TiGenix NV (Euronext Brussels and Nasdaq: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.


Two products from the adipose-derived stem cell technology platform are currently in clinical development.


- Cx601 has successfully completed a Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States.


- Cx611 has completed a European Phase I safety trial and is currently preparing to initiate a Phase I/II clinical trial in severe sepsis in Europe in the fourth quarter of 2016.


Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI).


In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication.


TiGenix is based in Leuven, Belgium, and has operations in Madrid, Spain.





Latest News

13 March 2017 - TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction (EN - NL - FR)

9 March 2017 - TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial (EN - NL - FR)

7 March 2017 - TiGenix Receives Positive Feedback from the FDA on Cx601 Global Phase III Trial Protocol (EN - NL - FR)

6 March 2017 - TiGenix Provides Update on Cx601 Marketing Authorization Application procedure in Europe (EN - NL - FR)

1 March 2017 - TiGenix to present at Cowen’s 37th Annual Health Care Conference in Boston (EN - NL - FR)


Company slide deck

2017 - Corporate Presentation

Management presentations

Cowen Health Care Conference webcast, 7 March 2017 (video available until 07/04/2017)

Presentation Brussels, 6 February 2017

Nasdaq CEO Signature Series Interview with Eduardo Bravo

First Half 2016 Business and Financial Update

ECCO Plenary ADMIRE-CD presentation

TiGenix ECCO Symposium presentations

Interview with De Tijd, 23 September 2015

Mediafin Investor Night (ENG - FR), 23 September 2015

HY15 results webcast presentation 15 September 2015

1H 2015 results webcast recording, September 2015

TiGenix Cx601 ADMIRE-CD Top-Line Results Webcast, August 2015

Tigenix at Alliance for Regenerative Medicine Conference, March 2015

TiGenix on Kanaal Z television, November 2014